GAL and chronic obstructive pulmonary disease: Toxicity assessments show relatively low risks of cardiac arrhythmias (myricetin), but certain compounds (e.g., isoquercetin, GAL) present higher risks of hepatotoxicity, nephrotoxicity, and genotoxicity, limiting their long-term safety for use.